Table 4. Change in serological indicators of malaria and lymphatic filariasis exposure immediately following and one year after an LLIN distribution campaign in Nacala-a-Velha and Mecubúri Districts, Mozambique.
| Serological conversion rate | log Median Fluorescent Intensity (paired analysis) | Seroposivity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013 | 2014 | % change | p-value | 2013 | 2014 | % change | p-value | 2013 | 2014 | % change | p-value | |
| Nacala-a-Velha | ||||||||||||
| P. falciparum MSP-119 antigen | 2.263 | 2.271 | 0% | 0.50 | 3.688 | 3.782 | 3% | 0.208 | 80% | 80% | 0% | 0.99 |
| P. falciparum CSP antigen | 0.087 | 0.074 | -15% | 0.07 | 3.493 | 3.494 | 0% | 0.986 | 61% | 58% | -5% | 0.33 |
| P. falciparum LSA-1 antigen | 0.17 | 0.144 | -15% | 0.35 | 2.198 | 2.227 | 1% | 0.617 | 31% | 28% | -10% | 0.27 |
| P. vivax MSP-119 antigen | 0.002 | 0.001 | -38% | 0.20 | 2.279 | 2.238 | -2% | 0.24 | 3% | 2% | -37% | 0.37 |
| P. ovale MSP-119 antigen | 0.118 | 0.092 | -22% | 0.10 | 2.076 | 2.1 | 1% | 0.632 | 41% | 35% | -14% | 0.06 |
| P. malariae MSP-119 antigen | 0.068 | 0.051 | -24% | 0.03 | 2.689 | 2.641 | -2% | 0.556 | 46% | 40% | -14% | 0.04 |
| W. bancrofti Wb123 antigen | 0.074 | 0.054 | -27% | 0.01 | 2.502 | 2.402 | -4% | 0.16 | 50% | 43% | -15% | 0.02 |
| B. malayi Bm14 antigen | 0.031 | 0.026 | -17% | 0.08 | 2.282 | 2.191 | -4% | 0.323 | 37% | 32% | -12% | 0.16 |
| B. malayi Bm33 antigen | 0.169 | 0.131 | -22% | 0.03 | 3.087 | 3.002 | -3% | 0.066 | 67% | 61% | -10% | 0.04 |
| Strongyloides NIE antigen (control) | 0.125 | 0.114 | -8% | 0.26 | 3.265 | 3.198 | -2% | 0.278 | 58% | 56% | -4% | 0.53 |
| Mecubúri | ||||||||||||
| P. falciparum MSP-119 antigen | 2.382 | 2.151 | -10% | 0.42 | 3.764 | 3.741 | -1% | 0.729 | 81% | 80% | -2% | 0.61 |
| P. falciparum CSP antigen | 0.125 | 0.133 | 7% | 0.27 | 3.677 | 3.709 | 1% | 0.631 | 71% | 71% | 0% | 0.99 |
| P. falciparum LSA-1 antigen | 0.184 | 0.224 | 22% | 0.32 | 2.342 | 2.324 | -1% | 0.773 | 33% | 38% | 15% | 0.09 |
| P. vivax MSP-119 antigen | 0.003 | 0.001 | -53% | 0.07 | 2.331 | 2.211 | -5% | 9E-04 | 4% | 2% | -54% | 0.04 |
| P. ovale MSP-119 antigen | 0.125 | 0.121 | -3% | 0.43 | 2.153 | 2.114 | -2% | 0.412 | 43% | 42% | -2% | 0.78 |
| P. malariae MSP-119 antigen | 0.095 | 0.094 | -1% | 0.46 | 2.919 | 2.912 | 0% | 0.918 | 56% | 54% | -3% | 0.59 |
| W. bancrofti Wb123 antigen | 0.048 | 0.039 | -19% | 0.05 | 2.321 | 2.203 | -5% | 0.043 | 41% | 35% | -15% | 0.03 |
| B. malayi Bm14 antigen | 0.044 | 0.03 | -31% | 8.E-04 | 2.438 | 2.289 | -6% | 0.12 | 45% | 34% | -23% | 2.E-04 |
| B. malayi Bm33 antigen | 0.246 | 0.101 | -59% | 2.E-09 | 3.146 | 2.885 | -8% | 9E-09 | 76% | 55% | -27% | 1.E-13 |
| Strongyloides NIE antigen (control) | 0.163 | 0.105 | -35% | 9.E-04 | 3.43 | 3.242 | -5% | 0.005 | 65% | 54% | -17% | 8.E-05 |
P-values for differences in serological conversion rate were derived with a normal distribution test, log Median Fluorescent Intensity with a two-sample t-test, and seropositivity with Pearson's chi-squared test